Clicky

Vera Therapeutics, Inc.(VERA)

Description: Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.


Keywords: Biotechnology Life Sciences Health Care Immunoglobulin A Nephropathy

Home Page: veratx.com

VERA Technical Analysis

8000 Marina Boulevard
Brisbane, CA 94005
United States
Phone: 650 770 0077


Officers

Name Title
Dr. Marshall Fordyce M.D. Founder, Pres, CEO & Director
Mr. Sean P. Grant M.B.A. Chief Financial Officer
Dr. Celia Lin M.D. Chief Medical Officer
Mr. Joseph R. Young M.B.A. Sr. VP of Fin. & Chief Accounting Officer
Mr. Julien E. Capers J.D. VP & Head of Legal
Ms. Kelly Rauber VP & Head of HR
Mr. Tom Doan Sr. VP of Devel. Operations
Ms. Lauren Frenz Chief Bus. Officer
Dr. Joanne Curley Ph.D. Chief Devel. Officer

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.3088
Price-to-Sales TTM: 0
IPO Date: 2021-05-14
Fiscal Year End: December
Full Time Employees: 41
Back to stocks